
Hep C 5-Question Quiz: What Would WHO Do?
HCV testing in HIV-infected men who have sex with men should be conducted every 2 years. True or False?
In this month’s quiz, we cover hepatitis C testing recommendations for HIV-infected men, choosing a direct-acting antiviral (DAA) regimen for a kidney transplant patient, patient-friendly descriptions of DAA mechanisms of action, and more. Ready to test your knowledge? Let’s get started.
Question 1.
Answer: C. Once yearly
According to
Question 2.
Answer: B. Glecaprevir/pibrentasvir for 12 weeks
A daily fixed-dose combination of glecaprevir/pibrentasvir for 12 weeks is currently recommended as a regimen for both treatment-naive and treatment-experienced kidney transplant patients with HCV genotype 2-6, with or without compensated cirrhosis. An alternative regimen for these patients would be 12 weeks of daily daclatasvir plus sofosbuvir, along with a low initial dose of ribavirin that can be increased as tolerated.
The glecaprevir/pibrentasvir regimen is also recommended for kidney transplant patients with the more common genotype 1; for those patients, ledipasvir/sofosbuvir is also a recommended option.
Question 3.
Answer: D. Telaprevir
WHO removed recommendations for the protease inhibitors boceprevir and telaprevir in its most
Question 4.
Answer: A. They directly target HCV to stop it from making copies of itself
Nucleoside and nucleotide NS5B polymerase inhibitors directly target HCV to stop it from making copies of itself in the liver, according to
Question 5.
Answer: NS3/4A protease inhibitors
Glecaprevir and voxilaprevir are both third-generation NS3/4A protease inhibitors. They are pan-genotypic, meaning they have high antiviral activity, and they result in cure rates over 95% when combined with an NS5A inhibitor. The availability of direct-acting antiviral combinations that include pan-genotypic, third-generation NS3/4A inhibitors represents an opportunity to treat patients with HCV infection without the need for prior genotype testing, according to a recent report in the journal
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.